Allogene Therapeutics Inc (NASDAQ: ALLO) has seen a decline in its stock price by -7.08 in relation to its previous close of 4.38. However, the company has experienced a -5.13% decline in its stock price over the last five trading sessions. Zacks Investment Research reported 2024-03-15 that Allogene’s (ALLO) fourth-quarter earnings beat estimates, but sales miss the mark. Management expects operating expenses for 2024 to be around $280 million.
Is It Worth Investing in Allogene Therapeutics Inc (NASDAQ: ALLO) Right Now?
ALLO has 36-month beta value of 0.80. Analysts have mixed views on the stock, with 2 analysts rating it as a “buy,” 1 as “overweight,” 1 as “hold,” and 0 as “sell.”
The public float for ALLO is 104.41M, and currently, short sellers hold a 26.58% ratio of that float. The average trading volume of ALLO on April 03, 2024 was 2.77M shares.
ALLO’s Market Performance
ALLO stock saw a decrease of -5.13% in the past week, with a monthly decline of -17.61% and a quarterly a decrease of 26.79%. The volatility ratio for the week is 6.13%, and the volatility levels for the last 30 days are 7.86% for Allogene Therapeutics Inc (ALLO). The simple moving average for the past 20 days is -14.14% for ALLO’s stock, with a 5.59% simple moving average for the past 200 days.
Analysts’ Opinion of ALLO
Citigroup gave a rating of “Buy” to ALLO, setting the target price at $7 in the report published on December 08th of the previous year.
ALLO Trading at -7.66% from the 50-Day Moving Average
After a stumble in the market that brought ALLO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -40.93% of loss for the given period.
Volatility was left at 7.86%, however, over the last 30 days, the volatility rate increased by 6.13%, as shares sank -25.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +31.72% upper at present.
During the last 5 trading sessions, ALLO fell by -5.13%, which changed the moving average for the period of 200-days by -18.36% in comparison to the 20-day moving average, which settled at $4.67. In addition, Allogene Therapeutics Inc saw 26.79% in overturn over a single year, with a tendency to cut further gains.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ALLO starting from Parker Geoffrey M., who purchase 190 shares at the price of $3.60 back on Jan 30 ’24. After this action, Parker Geoffrey M. now owns 819,590 shares of Allogene Therapeutics Inc, valued at $683 using the latest closing price.
MESSEMER DEBORAH M., the Director of Allogene Therapeutics Inc, sale 18,640 shares at $2.70 during a trade that took place back on Dec 18 ’23, which means that MESSEMER DEBORAH M. is holding 62,456 shares at $50,317 based on the most recent closing price.
Stock Fundamentals for ALLO
Current profitability levels for the company are sitting at:
- -1965.17 for the present operating margin
- -68.24 for the gross margin
The net margin for Allogene Therapeutics Inc stands at -2021.38. The total capital return value is set at -0.52.
Based on Allogene Therapeutics Inc (ALLO), the company’s capital structure generated 0.16 points at debt to capital in total, while cash flow to debt ratio is standing at -2.5. The debt to equity ratio resting at 0.19. The interest coverage ratio of the stock is 859.09.
Currently, EBITDA for the company is -287.05 million with net debt to EBITDA at -0.04. When we switch over and look at the enterprise to sales, we see a ratio of 4376.07. The liquidity ratio also appears to be rather interesting for investors as it stands at 12.58.
Conclusion
To put it simply, Allogene Therapeutics Inc (ALLO) has had a mixed performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
